UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 16.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 604,321 shares of the company's stock after buying an additional 87,502 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.16% of LifeStance Health Group worth $4,454,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in LFST. Blue Trust Inc. boosted its holdings in shares of LifeStance Health Group by 124.4% in the 4th quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock valued at $27,000 after buying an additional 2,122 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of LifeStance Health Group in the 4th quarter valued at approximately $87,000. Cibc World Markets Corp acquired a new stake in shares of LifeStance Health Group in the 4th quarter valued at approximately $96,000. Forum Financial Management LP acquired a new stake in shares of LifeStance Health Group in the 4th quarter valued at approximately $110,000. Finally, Handelsbanken Fonder AB acquired a new stake in shares of LifeStance Health Group in the 4th quarter valued at approximately $128,000. Institutional investors and hedge funds own 85.50% of the company's stock.
LifeStance Health Group Stock Performance
LFST traded down $0.02 during trading hours on Thursday, reaching $5.93. The company's stock had a trading volume of 1,350,248 shares, compared to its average volume of 1,595,020. LifeStance Health Group, Inc. has a 52 week low of $4.64 and a 52 week high of $8.61. The company's 50-day moving average is $6.28 and its 200-day moving average is $7.10. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. The firm has a market cap of $2.31 billion, a PE ratio of -22.81 and a beta of 1.22.
Insider Buying and Selling at LifeStance Health Group
In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.90, for a total value of $130,030.50. Following the transaction, the insider now directly owns 339,810 shares of the company's stock, valued at $2,344,689. This represents a 5.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 3.20% of the company's stock.
Analysts Set New Price Targets
Several research firms have recently commented on LFST. UBS Group raised LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 price objective for the company in a report on Tuesday, May 27th. Canaccord Genuity Group started coverage on LifeStance Health Group in a research note on Thursday, April 3rd. They issued a "buy" rating and a $8.00 price target on the stock. William Blair restated an "outperform" rating on shares of LifeStance Health Group in a research note on Friday, February 28th. Finally, KeyCorp started coverage on LifeStance Health Group in a research note on Tuesday, April 8th. They issued an "overweight" rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, LifeStance Health Group presently has a consensus rating of "Moderate Buy" and an average price target of $8.50.
View Our Latest Analysis on LifeStance Health Group
About LifeStance Health Group
(
Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Read More
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
